NEKTAR THERAPEUTICS NKTR

Healthcare Biotechnology

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

NDAQ:NKTR - Post by User

NEKTAR THERAPEUTICS

<< Previous

Bullboard Posts

Next >>

(4)
•••

Post by AviseAnalyticson Mar 21, 2022 9:06am

189 Views

Post# 34530790

WHAT’S NEXT FOR NEKTAR THERAPEUTICS?

$NKTR

Nektar Therapeutics (NASDAQ: NKTR) faced a setback with its crucial study of bempegaldesleukin in combination with Opdivo (nivolumab), failing to meet the primary endpoints of progression-free survival (PFS), objective response rate (ORR) and Overall Survival (OS).

What's next for the Company?

Read on to find out more!

https://www.aviseanalytics.com/whats-next-for-nektar-therapeutics/

<< Previous

Bullboard Posts

Next >>

A leading provider of integrated drone solutions across North America